jRCT2071200104进行中（未招募）不适用
Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer With or without Actionable Genomic Alterations (TROPION-Lung01)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 590
- 主要终点
- Progression-free Survival (PFS) As Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.1 Following DS-1062a Versus Docetaxel
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Sign and date the inform consent form (ICF) prior to the start of any study specific qualification procedures.
- •Adults >=18 years (if the legal age of consent is >18 years old, then follow local regulatory requirements)
- •Life expectancy >=3 months
- •Has pathologically documented-Stage IIIB, IIIC, or stage IV NSCLC disease with or without actionable genomic alterations (AGA) at the time of randomization (based on the American Joint Committee on Cancer, Eighth Edition) and meets following criteria for NSCLC:
- •1.Participants without AGA
- •a.Must have documented negative test results for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK).
- •b.Must have no known genomic alterations in ROS proto-oncogene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), proto oncogene B-raf (BRAF), mesenchymal-epithelial transition (MET) exon 14 skipping, or rearranged during transfection (RET).
- •2.Participants with AGA
- •a.Must have one or more documented actionable genomic alteration(s): EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, or RET.
- •Has documentation of radiographic disease progression while on or after receiving the most recent treatment regimen for advanced or metastatic NSCLC.
- •Participant without AGA must meet 1 of the following prior therapy requirements for advanced or metastatic NSCLC:
- •1.Received platinum-based chemotherapy in combination with alpha-PD-1/alpha-PD-L1 monoclonal antibody as the only prior line of therapy
- •a.Includes participants who received prior platinum-based chemotherapy with or without radiotherapy with maintenance alpha-PD-1/alpha-PD-L1 monoclonal antibody for Stage III disease and relapsed/progressed within 6 months from the last dose of platinum-based chemotherapy
- •b.Includes participants who received prior platinum-based chemotherapy with or without radiotherapy (with or without maintenance alpha-PD-1/alpha-PD-L1 monoclonal antibody) for Stage III disease and subsequently received alpha-PD-1/alpha-PD-L1 monoclonal antibody therapy (with or without platinum-based chemotherapy) for recurrent disease
- •2.Received platinum-based chemotherapy and alpha-PD-1/alpha-PD-L1 monoclonal antibody (in either order) sequentially as the only 2 prior lines of therapy.
- •Participants with AGA must meet the following for advanced or metastatic NSCLC:
- •1.Participants who have been treated with 1 or 2 prior lines of applicable targeted therapy that is locally approved for the participant's genomic alteration at the time of screening
- •a.Participants who have tumors with EGFR L858R or exon 19 deletion mutations must have received prior Osimertinib.
- •b.Those who received a targeted agent as adjuvant therapy for early-stage disease must have relapsed or progressed while on the treatment or within 6 months of the last dose OR received at least one additional course of targeted therapy for the same genomic alteration (which may or may not be same agent used in the adjuvant setting) for relapsed/progressive disease.
- •c.Participants who have been treated with a prior TKI must receive additional approved targeted therapy, if locally available and clinically appropriate, for the applicable genomic alteration, or the participant will not be allowed in the study.
- •2.Participants who have received platinum-based chemotherapy as the only prior line of cytotoxic therapy:
- •a.One platinum-containing regimen for advanced disease
- •b.Those who received a platinum-containing regimen as adjuvant therapy for early-stage disease must have relapsed or progressed while on the treatment or within 6 months of the last dose OR received at least one additional course of platinum-containing therapy (which may or may not be same as in the adjuvant setting) for relapsed/progressive disease.
- •3.May have received up to one alpha-PD-1/alpha-PD-L1 monoclonal antibody alone or in combination with a cytotoxic agent.
- •Must undergo a pre-treatment tumor biopsy procedure or if available, tumor tissue previously retrieved from a biopsy procedure performed within 2 years prior to the participant signing informed consent and that has a minimum of 10 x 4 micron sections or a tissue block equivalent of 10 x 4 micron sections may be substituted for the pre-treatment biopsy procedure during Screening. If a documented law or regulation prohibits (or does not approve) sample collection, then such samples will not be collected/submitted.
- •Measurable disease based on local imaging assessment using RECIST v1.1
- •Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 at Screening
- •Within 7 days before randomization, has adequate bone marrow, hepatic, and renal function
- •Left ventricular ejection fraction (LVEF) >=50% by either echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before randomization
- •Adequate blood clotting function defined as international normalized ratio/prothrombin time and either partial thromboplastin or activated partial thromboplastin time <=1.5 x upper limit of normal (ULN)
- •Adequate treatment washout period before randomization
- •Females of childbearing potential must have a negative serum pregnancy test at screening and must be willing to use highly effective birth control from the time of enrollment up to 7 months after the last dose of DS-1062a or for at least 6 months after the last dose of docetaxel
- •Males must be surgically sterile or must use a condom in addition to highly effective birth control if his partners are of reproductive potential from the time of enrollment and for at least 4 months after last dose of DS-1062a or for at least 6 months after the last dose of docetaxel
- •Male participants must not freeze or donate sperm from the time of Screening and throughout the study period and for at least 4 months after the last dose of DS-1062a or for at least 6 months after the last dose of docetaxel
- •Female participants must not donate, or retrieve for their own use, ova from the time of Screening and throughout the study period and for at least 7 months after the last dose of DS-1062a and for at least 6 months after the last dose of docetaxel
排除标准
- •Mixed small-cell lung cancer (SCLC) and NSCLC histology
- •Has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Participants with clinically inactive brain metastases may be included in the study. Participants with treated brain metastases who are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy
- •Has leptomeningeal carcinomatosis or metastasis-Had prior treatment with:
- •1.Any agent including antibody drug conjugate (ADC) containing a chemotherapeutic agent targeting topoisomerase I
- •2.TROP2-targeted therapy
- •3.Docetaxel
- •Had prior treatment with platinum-based chemotherapy and prior immunotherapy for Stage II NSCLC disease (eg, in the neo-adjuvant or adjuvant setting) without subsequently meeting the prior therapy requirements for Stage III or metastatic NSCLC disease
- •Has NSCLC disease that is eligible for definitive local therapy alone-Has uncontrolled or significant cardiac disease, including:
- •Mean QT interval corrected for heart rate using Fridericia's formula >470 msec (based on the average of Screening triplicate 12-lead electrocardiogram [ECG] determinations)
- •2.Myocardial infarction or uncontrolled/unstable angina within 6 months before randomizationc.
- •3.Congestive heart failure (CHF) (New York Heart Association Class II to IV) at Screening. Participants with a history of Class II to IV CHF prior to Screening, must have returned to Class I CHF and have LVEF >=50% (by either an ECHO or MUGA scan within 28 days before randomization) in order to be eligibled.
- •4.Uncontrolled or significant cardiac arrhythmiae.
- •5.LVEF <50% by ECHO or MUGA scan within 28 days before randomizationf.
- •6.Uncontrolled hypertension (resting systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg) within 28 days before randomization
- •Has a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening
- •Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months before randomization, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc.), or any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement (ie, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc.), or prior pneumonectomy
- •Significant third-space fluid retention (for example ascites or pleural effusion) and is not amenable for required repeated drainage.
- •Clinically significant corneal disease
- •Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals; suspected infections (eg, prodromal symptoms); or inability to rule out infections
- •Has known human immunodeficiency virus (HIV) infection that is not well controlled
- •Has an active or uncontrolled hepatitis B and/or hepatitis C infection, is positive for hepatitis B or C virus based on the evaluation of results of tests for hepatitis B (hepatitis B surface antigen [HBsAg], anti-hepatitis B surface antibody [anti-HBs], anti- hepatitis B core antibody [anti-HBc], or hepatitis B virus [HBV] DNA), and/or hepatitis C infection (as per hepatitis C virus [HCV] RNA) within 28 days of randomization
- •Has a history of malignancy, other than NSCLC, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated, with no evidence of disease for >=3 years
- •Toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet improved to NCI-CTCAE version 5.0 Grade <=1 or baseline-Has a history of severe hypersensitivity reactions to either the drug substances, inactive ingredients (including but not limited to polysorbate 80) of DS-1062a or docetaxel, or monoclonal antibodies
- •Pregnant or breastfeeding
- •Has substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions
结局指标
主要结局
Progression-free Survival (PFS) As Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.1 Following DS-1062a Versus Docetaxel
时间窗: From randomization until disease progression or death (whichever occurs first), up to approximately 43 months
PFS is defined as the time from randomization to the earlier of the dates of the first documentation of radiographic progressive disease or death due to any cause.
Overall Survival (OS) Following DS-1062a Versus Docetaxel
时间窗: From randomization until date of death due to any cause, up to approximately 43 months
OS is defined as the time from randomization to the date of death due to any cause.
次要结局
- Progression-free Survival (PFS) As Assessed by Investigator Per RECIST v1.1 Following DS-1062a Versus Docetaxel(From randomization until disease progression or death (whichever occurs first), up to approximately 43 months)
- Objective Response Rate (ORR) As Assessed by Blinded Independent Central Review (BICR) and Investigator As Per RECIST v1.1 Following DS-1062a Versus Docetaxel(From randomization until disease progression or death (whichever occurs first), up to approximately 43 months)
- Duration of Response (DOR) As Assessed by Blinded Independent Central Review (BICR) and Investigator As Per RECIST v1.1 Following DS-1062a Versus Docetaxel(From date of first objective response (CR or PR) to date of first radiographic disease progression or death due to any cause (whichever occurs first), up to approximately 43 months)
- Disease Control Rate (DCR) As Assessed by Blinded Independent Central Review (BICR) and Investigator As Per RECIST v1.1 Following DS-1062a Versus Docetaxel(From randomization until disease progression or death (whichever occurs first), up to approximately 43 months)
- Time to Response (TTR) As Assessed by Blinded Independent Central Review (BICR) and Investigator As Per RECIST v1.1 Following DS-1062a Versus Docetaxel(From randomization to date of first objective response (CR or PR), up to approximately 43 months)
- Time to Deterioration (TTD) Following DS-1062a Versus Docetaxel(Baseline and assessed on Day 15 of each cycle until disease progression or end of treatment (each cycle is 21 days) and then once more at +90 days end of treatment)
- Percentage of Participants Who Reported Treatment-emergent Adverse Events Following DS-1062a Versus Docetaxel(Baseline up to 35 days after last study dose, up to approximately 43 months)
- Pharmacokinetic Parameter Area Under the Plasma Concentration-Time Curve (AUC) of DS-1062a, Total Anti-TROP2 Antibody, and Active Metabolite MAAA-1181a(Cycle 1, Day 1: predose and 30 minutes, 3 hours, 5 hours, and 7 hours postdose and Days 2, 4, 8, and 15; Cycles 2, 3, 4, 6, and 8, Day 1: predose and 1 hour postdose (each cycle is 21 days))
研究者
相似试验
已完成
2 期
A randomized phase 2 study of Docetaxel with or without Bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced non-squamous non-small-cell lung canceron-small cell lung cancerJPRN-UMIN000004715West Japan Oncology Group100
已完成
不适用
Randomized Phase II Trial Comparing Docetaxel with weekly Paclitaxel and Carboplatin in Elderly Patients with Non-Small Cell Lung CancerJPRN-UMIN000002616Tohoku University Hospital80
进行中（未招募）
1 期
Phase II Trial of Docetaxel in Patients With Metastatic or Inoperable Medullary Thyroid CancerMetastatic or inoperable medullary thyroid cancerEUCTR2006-005301-63-ATniversity Hospital Vienna
已完成
3 期
A Phase III Study of Docetaxel and S-1 versus S-1 in the Treatment of Advanced Gastric CancerGastric CancerJPRN-C000000251Japan Clinical Cancer Research Organization628
已完成
2 期
A Randomized phase II study of docetaxel versus weekly carboplatin and CPT-11 for previously treated Non-Small cell lung cancerJPRN-C000000147West Japan Oncology Group64